about
Fanconi syndrome in a patient with β-thalassemia major after using deferasirox for 27 months.Iron redistribution as a therapeutic strategy for treating diseases of localized iron accumulation.Association of Iron Overload with Oxidative Stress, Hepatic Damage and Dyslipidemia in Transfusion-Dependent β-Thalassemia/HbE Patients.Iron overload in sickle cell disease.Clinically approved iron chelators influence zebrafish mortality, hatching morphology and cardiac function.Comparison of various iron chelators and prochelators as protective agents against cardiomyocyte oxidative injury.Polymeric nanocarriers for the treatment of systemic iron overload.Secondary haemochromatosis in a haemodialysis patient.Pathophysiology and Clinical Manifestations of the β-Thalassemias.Assessment of hepatic and pancreatic iron overload in pediatric Beta-thalassemic major patients by t2* weighted gradient echo magnetic resonance imagingMRI evaluation of tissue iron burden in patients with beta-thalassaemia major.Characterization of cytoprotective and toxic properties of iron chelator SIH, prochelator BSIH and their degradation products.Pharmacogenomics and therapeutics of hemoglobinopathies.Influence of iron chelators on myocardial iron and cardiac function in transfusion-dependent thalassaemia: a systematic review and meta-analysis.Specific iron chelators determine the route of ferritin degradation.Individualizing fetal hemoglobin augmenting therapy for β-type hemoglobinopathies patients.TLc-A, the leading nanochelating-based nanochelator, reduces iron overload in vitro and in vivo.Effects of chelators (deferoxamine, deferiprone and deferasirox) on the growth of Klebsiella pneumoniae and Aeromonas hydrophila isolated from transfusion-dependent thalassemia patients.Novel near-infrared fluorescent integrin-targeted DFO analogue.Role of vitamin C as an adjuvant therapy to different iron chelators in young β-thalassemia major patients: efficacy and safety in relation to tissue iron overload.Transfusion-dependent thalassaemic patients with renal Fanconi syndrome due to deferasirox use.Hepatic Iron Quantification on 3 Tesla (3 T) Magnetic Resonance (MR): Technical Challenges and Solutions.Chelation of bismuth by combining desferrioxamine and deferiprone in rats.Grape seed extract alleviates high-fat diet-induced obesity and heart dysfunction by preventing cardiac siderosis.Histological and molecular evaluation of iron as degradable medical implant material in a murine animal model.A combination of an iron chelator with an antioxidant exerts greater efficacy on cardioprotection than monotherapy in iron-overload thalassemic mice.Dual T-type and L-type calcium channel blocker exerts beneficial effects in attenuating cardiovascular dysfunction in iron-overloaded thalassaemic mice.Comparison of the Hydroxylase Inhibitor Dimethyloxalylglycine and the Iron Chelator Deferoxamine in Diabetic and Aged Wound Healing.
P2860
Q33392822-0DAD3CB9-57F2-4810-B954-71E75F4CED66Q33555894-CE6F731F-4256-4F42-A8B9-146B655B440CQ33774553-575D32AA-8B4C-419C-A53A-20F6B41151E6Q33861129-4BDB7F8F-98BE-44D5-BCCD-3ED65FF4950AQ34351633-44171B4B-04D2-43DB-AA04-73108919C8B0Q34568034-D6D1E1D6-78B8-4ED4-88BE-7BE747A882EEQ35673632-3F412410-5DA5-4BC2-ABBB-DC8D03ABFDD9Q35905053-EBE024BE-544F-41FC-9A4C-9A1BDBC5F9EDQ36526536-A592BBE8-87CA-4213-81C2-1C7CA625EC2DQ36763442-8EA47F56-F0F1-4134-A2CA-89E187633D4AQ36915101-B429BE1D-C9F7-453D-903C-404A13144CD6Q36957543-535E64B1-4907-4C57-9F2B-F73D4CB1BE4CQ37084743-DD4CC051-12D5-46D9-854D-EB3759CB46EAQ37114840-5E7F104E-3776-46D7-BCDD-64AE70B89314Q37420521-188FBD7F-C2C3-44AD-814E-9635BC12986AQ38243173-B8F5E402-422B-4D44-A0A8-347104B472D8Q38797668-5DA1DCB2-42E9-4244-9379-11E3A10E6652Q38937817-D229B1DE-9B69-4495-B9CB-294753F67EADQ40044646-80BF635D-709A-41C3-A828-1FD2D5561F19Q40896307-5BBB6328-977F-4DB7-AB95-0BC35D2C5930Q41714289-D109AE80-ACBC-4136-B0E9-75E53AB45545Q41814500-AFAD8B13-BEFC-40C1-AFD5-9F184833E7FAQ46235553-B37027B8-B303-42AF-BDB2-72F3C2366AE2Q46942427-64C138A7-F9FF-491D-95AD-B41898097600Q46969113-D22DD87E-1E24-405F-99DB-BF119AC748ACQ47931907-570E72F5-4A72-4267-8FCC-E111AC94A28BQ53804215-16A19AFF-8A6B-4791-B5F9-AEE586CA83C3Q54778336-E20A28BA-A5AE-45C6-B30B-5FF2C33DD1A8
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Objectives and mechanism of iron chelation therapy.
@ast
Objectives and mechanism of iron chelation therapy.
@en
type
label
Objectives and mechanism of iron chelation therapy.
@ast
Objectives and mechanism of iron chelation therapy.
@en
prefLabel
Objectives and mechanism of iron chelation therapy.
@ast
Objectives and mechanism of iron chelation therapy.
@en
P2093
P356
P1476
Objectives and mechanism of iron chelation therapy.
@en
P2093
Abraham M Konijn
Chaim Hershko
Gabriela Link
Z Ioav Cabantchik
P304
P356
10.1196/ANNALS.1345.015
P407
P577
2005-01-01T00:00:00Z